Wall Street Zen Downgrades Zimmer Biomet (NYSE:ZBH) to Hold

Zimmer Biomet (NYSE:ZBH) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

Several other brokerages have also recently issued reports on ZBH. Sanford C. Bernstein increased their target price on shares of Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a report on Thursday. Wells Fargo & Company dropped their price objective on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 29th. Citigroup reduced their price objective on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research note on Thursday, May 28th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Wednesday. Finally, JPMorgan Chase & Co. dropped their target price on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus price target of $103.53.

Zimmer Biomet Trading Down 0.0%

Shares of NYSE ZBH opened at $96.54 on Friday. Zimmer Biomet has a twelve month low of $79.12 and a twelve month high of $108.29. The firm has a market cap of $18.41 billion, a PE ratio of 23.49, a price-to-earnings-growth ratio of 3.07 and a beta of 0.45. The business has a fifty day simple moving average of $90.17 and a two-hundred day simple moving average of $90.15. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. The business had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business’s revenue was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Analysts expect that Zimmer Biomet will post 8.53 earnings per share for the current fiscal year.

Insider Activity at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider owned 27,251 shares in the company, valued at $2,252,022.64. The trade was a 15.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.28% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zimmer Biomet

Institutional investors have recently bought and sold shares of the company. DV Equities LLC purchased a new stake in shares of Zimmer Biomet during the 4th quarter valued at $25,000. Monetary Solutions Ltd acquired a new stake in shares of Zimmer Biomet in the 4th quarter worth $30,000. Gen Wealth Partners Inc purchased a new position in Zimmer Biomet during the 4th quarter worth $31,000. Flagship Harbor Advisors LLC acquired a new position in Zimmer Biomet during the 4th quarter valued at about $32,000. Finally, Elevation Wealth Partners LLC raised its stake in Zimmer Biomet by 145.9% in the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 229 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.